Exhibit 32.1
CERTIFICATIONS PURSUANT TO 18 U.S.C.
SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Dianthus Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Marino Garcia, President and Chief Executive Officer of the Company, and Ryan Savitz, Chief Financial Officer and Chief Business Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to our knowledge:
Date: |
March 21, 2024 |
By: |
/s/ Marino Garcia |
|
|
|
Marino Garcia |
|
|
|
President and Chief Executive Officer |
|
|
|
(Principal Executive Officer) |
Date: |
March 21, 2024 |
By: |
/s/ Ryan Savitz |
|
|
|
Ryan Savitz |
|
|
|
Chief Financial Officer and Chief Business Officer |
|
|
|
(Principal Financial Officer) |